肺动脉高压患者口服药物血流动力学正常化的治疗局限性PA5467六世- 54 - 5 63 SP - PA5467盟Shimokawahara Hiroto AU -松原,Hiromi盟——Hayashi Kazuna盟——Nishihara孝宏盟——信,Masahiro盟——Naito Takanori盟——Shigetoshi东盟——Tabuchi Isao盟——Munemasa Mitsuru Y1 - 2019/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/PA5467.abstract N2 -背景:肺动脉高压(PAH)有一个不良的预后，尽管可用的治疗选择。血流动力学的正常化将需要获得良好的预后。目的和目的:我们旨在调查肺动脉高压患者仅口服药物使血流动力学正常化的决定因素。方法:我们回顾性分析了190例在单一转诊中心接受肺动脉高压治疗的患者。观察治疗前后的血流动力学参数。随访时将患者分为平均肺动脉压(mPAP)<30mmHg的良好对照组和平均肺动脉压≧30mmHg的不良对照组。结果:原发性/遗传性82例，结缔组织病65例，先天性心脏病22例，门脉高压21例。mPAP从基线到随访显著降低(51±18.7 mmHg至34.1±15.2 mmHg, p;0.001)。mPAP的降低在PAH的病因之间没有差异。 The decrease of mPAP in combination treatments with parenteral prostanoid was significantly greater than that in patients treated with only oral drugs (22.5±2.0 mmHg vs.11.6±1.4 mmHg, p<0.001). Among the 76 patients treated with only oral drugs, mPAP before treatment in the poor control group was higher than that in another group (47.2 mmHg vs. 38.1 mmHg, p<0.001). The best cutoff value of mPAP before treatment for detecting mean PAP≦30mmHg after treatment was 39.5mmHg according to the receiver operating analysis (p=0.001).Conclusions: To achieve normalization of hemodynamics in PAH, parenteral prostanoid should be used in cases with baseline mPAP exceeding 40mmHg.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA5467.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -